This episode of '200: Tech Tales Found' delves into the remarkable journey of Medivation, a biotech company that rose from humble beginnings to develop Xtandi, a groundbreaking treatment for prostate cancer. Founded in 2004 by Dr. David Hung and Steve Gorlin, Medivation was driven by a deeply personal mission: to offer hope where traditional medicine had failed. Early setbacks, including the failure of their Alzheimer's drug Dimebon, nearly derailed the company until they pivoted to enzalutamide—later named Xtandi—a compound targeting advanced prostate cancer. Through resilience and strategic partnership with Astellas Pharma, Xtandi gained FDA approval in 2012 and quickly became a lifeline for thousands of men worldwide. Its success transformed Medivation into a biotech darling, sparking a fierce $14 billion bidding war among pharmaceutical giants like Sanofi, AstraZeneca, and ultimately Pfizer, which acquired the company in 2016. Xtandi continues to evolve, receiving expanded approvals over the years and offering extended survival rates for patients with hormone-sensitive and non-metastatic forms of the disease. Alongside Xtandi, Medivation’s pipeline included other promising drugs like Talazoparib for BRCA-mutated breast cancer, further cementing its legacy in oncology. The story also highlights Dr. David Hung’s unwavering commitment to innovation—he later led Axovant Sciences to tackle Alzheimer’s again—and Steve Gorlin’s continued influence in biotech investing. While Xtandi has saved countless lives, the episode touches on broader issues of drug pricing and access, reminding listeners that behind every medical breakthrough lies a complex interplay of science, business, ethics, and human emotion. Medivation’s rise is more than a corporate success story; it’s a testament to perseverance, vision, and the profound impact one company can have on global health.